Agomelatin Yetişkin Sıçanlarda Skopolamin kaynaklı Öğrenme ve Hafıza Bozukluğunu Tersine Çevirir

Objective: The antidepressant agomelatine agent is a melatonin receptor (MT1 and MT2) agonist serotonin (5-HT2C) antagonist. Increasing evidence shows that has neuroprotective neuromodulatory effects. In this study, the potential effects of in rats with scopolamine-induced cognitive impairment were investigated.Materials Methods: Adult male administered scopolamine (1 mg/kg) (40 for 21 days. After drug administration, subjected to new object recognition (NOR) Morris water maze (MWM) tests order evaluate behaviors. addition, brain-derived neurotrophic factor (BDNF) acetylcholine (ACh) levels hippocampus prefrontal cortex evaluated.Results: Scopolamine significantly decreased both spatial memory discrimination index (p<0.05). Agomelatine treatment increased performance exploration time, but did not affect (P>0.05). BDNF compared group (p<0.05, p<0.01, respectively). On other hand, there was no statistically significant difference between ACh groups (p>0.05).Conclusion: Taken together, these results demonstrated plays important role alleviating impairment. Therefore, we suggest may be prevention